R Wolk

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Oxidative stress in obstructive sleep apnoea
    Anna Svatikova
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur Heart J 26:2435-9. 2005
  2. doi request reprint Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects
    R Wolk
    Global Research and Development, Pfizer, New London, Connecticut, USA
    Clin Pharmacol Ther 86:430-7. 2009
  3. doi request reprint Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension
    Robert Wolk
    Pfizer Global Research and Development, Pfizer Inc, New London, CT 06320, USA
    Hypertension 53:1091-7. 2009
  4. ncbi request reprint Sleep and the metabolic syndrome
    Robert Wolk
    Cardiovascular Metabolic Diseases, Pfizer Global Research and Development, Eastern Point Road, MS 8260 2506, Groton, CT 06340, USA
    Exp Physiol 92:67-78. 2007
  5. ncbi request reprint Interactions between obstructive sleep apnea and the metabolic syndrome
    Anna Svatikova
    Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Curr Diab Rep 5:53-8. 2005
  6. ncbi request reprint Obesity, sleep apnea, and hypertension
    Robert Wolk
    Mayo Clinic, Rochester, Minn, USA
    Hypertension 42:1067-74. 2003
  7. ncbi request reprint Plasma adrenomedullin and obstructive sleep apnea
    Robert Wolk
    Mayo Clinic, Rochester, Minnesota, USA
    Am J Hypertens 17:74-6. 2004
  8. ncbi request reprint Cardiovascular consequences of obstructive sleep apnea
    Robert Wolk
    Mayo Clinic, Department of Medicine, Division of Cardiovascular Diseases and Division of Hypertension, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Chest Med 24:195-205. 2003
  9. ncbi request reprint Microarray studies of genomic oxidative stress and cell cycle responses in obstructive sleep apnea
    Michal S Hoffmann
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Antioxid Redox Signal 9:661-9. 2007
  10. ncbi request reprint Familial premature coronary artery disease mortality and obstructive sleep apnea
    Apoor S Gami
    Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Chest 131:118-21. 2007

Collaborators

  • Virend Somers
  • Mikolaj Winnicki
  • Eric J Olson
  • Bradley G Phillips
  • Anna Svatikova
  • Apoor S Gami
  • Michal S Hoffmann
  • Abu S Shamsuzzaman
  • Tomas Kara
  • Abu S M Shamsuzzaman
  • Christine Huyber
  • Prachi Singh
  • Daniel L Herold
  • Sreekumar Raghavakaimal
  • Stefanie Rader
  • Abel Romero-Corral
  • Luis A Juncos
  • Joseph P McConnell
  • Eddie L Greene
  • Lilach O Lerman
  • Michal Pohanka
  • Kevin A Bybee
  • Allan S Jaffe
  • Carolyn J Duenwald
  • Maria E Otto
  • Hui H Wang
  • Mark J Magera
  • Ravinder J Singh
  • Paola Lanfranchi
  • Valentina Accurso

Detail Information

Publications19

  1. ncbi request reprint Oxidative stress in obstructive sleep apnoea
    Anna Svatikova
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur Heart J 26:2435-9. 2005
    ..We tested the hypothesis that measures of oxidative stress are increased in otherwise healthy subjects with OSA when compared to closely matched OSA-free control subjects...
  2. doi request reprint Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects
    R Wolk
    Global Research and Development, Pfizer, New London, Connecticut, USA
    Clin Pharmacol Ther 86:430-7. 2009
    ..No changes in blood pressure (BP) were observed. The possible effects of higher CP-800,569 doses on aldosterone and cortisol levels could not be excluded. The results of this study may be useful in CP-800,569 dose selection...
  3. doi request reprint Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension
    Robert Wolk
    Pfizer Global Research and Development, Pfizer Inc, New London, CT 06320, USA
    Hypertension 53:1091-7. 2009
    ..In conclusion, PF-00489791 causes a clinically meaningful and sustained BP lowering in patients with hypertension. It is generally safe and well tolerated at the clinically efficacious doses...
  4. ncbi request reprint Sleep and the metabolic syndrome
    Robert Wolk
    Cardiovascular Metabolic Diseases, Pfizer Global Research and Development, Eastern Point Road, MS 8260 2506, Groton, CT 06340, USA
    Exp Physiol 92:67-78. 2007
    ....
  5. ncbi request reprint Interactions between obstructive sleep apnea and the metabolic syndrome
    Anna Svatikova
    Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Curr Diab Rep 5:53-8. 2005
    ....
  6. ncbi request reprint Obesity, sleep apnea, and hypertension
    Robert Wolk
    Mayo Clinic, Rochester, Minn, USA
    Hypertension 42:1067-74. 2003
    ....
  7. ncbi request reprint Plasma adrenomedullin and obstructive sleep apnea
    Robert Wolk
    Mayo Clinic, Rochester, Minnesota, USA
    Am J Hypertens 17:74-6. 2004
    ..Obstructive sleep apnea (OSA) is associated with hypertension. The vasorelaxing peptide adrenomedullin (ADM) may counteract effects of OSA-induced release of vasopressor substances...
  8. ncbi request reprint Cardiovascular consequences of obstructive sleep apnea
    Robert Wolk
    Mayo Clinic, Department of Medicine, Division of Cardiovascular Diseases and Division of Hypertension, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Chest Med 24:195-205. 2003
    ..g., central obesity, age, and male gender). Treating sleep apnea may help to achieve better clinical control in these diseases and may improve long-term cardiovascular prognosis...
  9. ncbi request reprint Microarray studies of genomic oxidative stress and cell cycle responses in obstructive sleep apnea
    Michal S Hoffmann
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Antioxid Redox Signal 9:661-9. 2007
    ..These overnight changes in OSA patients are suggestive of activation of several mechanisms to modulate, and adapt to, increased ROS developing in response to the frequent episodes of intermittent hypoxia...
  10. ncbi request reprint Familial premature coronary artery disease mortality and obstructive sleep apnea
    Apoor S Gami
    Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Chest 131:118-21. 2007
    ..A family history of premature CAD and related mortality is an independent risk factor for the development of CAD. We hypothesized that OSA is associated with a family history of premature mortality from ischemic heart disease...
  11. ncbi request reprint Association between plasma adiponectin levels and unstable coronary syndromes
    Robert Wolk
    Division of Cardiovascular Diseases, Mayo Clinic, 1216 Second Street SW, Rochester, MN 55902, USA
    Eur Heart J 28:292-8. 2007
    ..This study evaluated the association between adiponectin and ACS...
  12. ncbi request reprint Sleep-disordered breathing and cardiovascular disease
    Robert Wolk
    Mayo Clinic, Rochester, MN 55902, USA
    Circulation 108:9-12. 2003
  13. ncbi request reprint Sleep and cardiovascular disease
    Robert Wolk
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Curr Probl Cardiol 30:625-62. 2005
    ..Further understanding of specific pathophysiological pathways linking sleep disorders to cardiovascular disease is important for developing therapeutic strategies and may have important implications for cardiovascular chronotherapeutics...
  14. ncbi request reprint Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea
    Robert Wolk
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Mayo Foundation, St Mary s Hospital, DO 4 350, 1216 Second Street SW, Rochester, MN 55902, USA
    Obes Res 13:186-90. 2005
    ..The purpose of the study was to investigate whether OSA affected plasma levels of adiponectin, which might help explain OSA-associated cardiovascular morbidity...
  15. ncbi request reprint Serum amyloid a in obstructive sleep apnea
    Anna Svatikova
    Mayo Foundation, Rochester, Minn, USA
    Circulation 108:1451-4. 2003
    ..Serum amyloid A (SAA) protein has recently been linked to the development of atherosclerosis, stroke, diabetes, and dementia. We tested the hypothesis that plasma SAA levels are increased in otherwise healthy subjects with OSA...
  16. ncbi request reprint Plasma homocysteine in obstructive sleep apnoea
    Anna Svatikova
    Division of Cardiovascular Disease, Mayo Clinic and Mayo Foundation, 200 1st St SW, Rochester, MN 55901, USA
    Eur Heart J 25:1325-9. 2004
    ..We hypothesised that plasma homocysteine would be higher in OSA patients than in control subjects, would increase further during sleep, and decrease after treatment with continuous positive airway pressure (CPAP)...
  17. ncbi request reprint Cardiac troponin T in obstructive sleep apnea
    Apoor S Gami
    Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Chest 125:2097-100. 2004
    ..We tested the hypothesis that severe nocturnal hypoxia in patients with OSA causes myocyte necrosis as evidenced by increases in cardiac troponin T...
  18. ncbi request reprint Circulating free nitrotyrosine in obstructive sleep apnea
    Anna Svatikova
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 287:R284-7. 2004
    ..This observation suggests that repetitive hypoxemia during OSA does not result in increased NO-mediated oxidative/nitrosative stress in otherwise healthy subjects with OSA...
  19. ncbi request reprint Elevated C-reactive protein in patients with obstructive sleep apnea
    Abu S M Shamsuzzaman
    Mayo Clinic Rochester, Rochester, MN 59905, USA
    Circulation 105:2462-4. 2002
    ..Inflammatory processes associated with OSA may contribute to cardiovascular morbidity in these patients. We tested the hypothesis that OSA patients have increased plasma C-reactive protein (CRP)...